Evidence map›Paper›PMID 39736321›Full record

ArticleVirologica Sinica2025

The potential mechanisms and material basis of Fuzheng Jiedu decoction broad-spectrum inhibiting coronaviruses.

Ke Liu, Bixia Hong, Shi-Ting He, Siying Du, Jiayi Ke, Lili Tian, Tao Tao, Yihan Zhang, Kelin Li, Han Chang and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virologica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Drugs against broad-spectrum of coronaviruses.Frontiers in immunology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ke LiuCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Bixia HongSchool of Basic Medical Science, State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou 511436, China.
Shi-Ting HeCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Siying DuCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Jiayi KeCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Lili TianCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Tao TaoCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Yihan ZhangCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Kelin LiCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Han ChangCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Mengzhe LiCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Xiaoping AnCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Lihua SongCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Zhongde ZhangState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong 510006, China.
Liang LiuState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong 510006, China.
Hudan PanState Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong 510006, China. Electronic address: hdpan@gzucm.edu.cn.
Huahao FanCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China; School of Life Sciences, Tianjin University, Tianjin 300072, China. Electronic address: fanhuahao@tju.edu.cn.
Yigang TongCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. Electronic address: tongyigang@mail.buct.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traditional Chinese medicine has unique advantages in preventing and treating COVID-19, and Fuzheng Jiedu decoction (FZJDD) was reported to be effective against COVID-19 in clinical trials. To investigate the potential mechanisms and material basis of FZJDD against SARS-CoV-2, we performed SARS-CoV-2 target protein inhibition analyses and a metabolite full spectrum analysis of FZJDD. Interestingly, FZJDD was found to block the binding of SARS-CoV-2 Spike protein with the receptor ACE2 and inhibit the activity of SARS-CoV-2 3CLpro. Moreover, FZJDD can regulate the TNF and the MAPK signaling pathway to inhibit the inflammatory response and alleviate the "cytokine storm". A total of 298 compounds were identified in FZJDD, among them, caffeic acid and octyl gallate were found to be the potential therapeutic agents of FZJDD. Importantly, FZJDD can broadly inhibit coronavirus infection, including SADS-CoV and porcine epidemic diarrhea virus (PEDV) live viruses, SARS-CoV, MERS-CoV, and SARS-CoV-2 mutant pseudotyped viruses, which might be ascribed to the broad-spectrum anti-coronavirus activity of caffeic acid and octyl gallate. In conclusion, this study reveals the mechanisms and material basis of FZJDD against SARS-CoV-2 and identifies the broad-spectrum anti-coronavirus activity of FZJDD for the first time. Our data provide empirical evidence for the development and application of FZJDD.

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentDrugs, Chinese HerbalSARS-CoV-2Angiotensin-Converting Enzyme 2AnimalsCaffeic AcidsCoronavirus 3C ProteasesCOVID-19Gallic AcidHumansSpike Glycoprotein, CoronavirusVero CellsACE2 protein, humanAngiotensin-Converting Enzyme 2Antiviral Agentscaffeic acidCaffeic AcidsCoronavirus 3C ProteasesDrugs, Chinese HerbalGallic AcidSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Broad-spectrum anti-coronavirusCaffeic acidFuzheng jiedu decoctionOctyl gallateSARS-CoV-2Traditional Chinese medicine

Identifiers

PMID39736321
PMCPMC11962989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.